Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery-Reference-Cited by-同舟云学术

Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery

Published:2015-03-18 Issue:2 Volume:7 Page:101-112
ISSN:1534-6250
Container-title:Current Treatment Options in Infectious Diseases
language:en
Short-container-title:Curr Treat Options Infect Dis

Author:

Doblecki-Lewis Susanne,Cohen Stephanie,Liu Albert

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40506-015-0046-4.pdf

Reference84 articles.

1. Centers for Disease Control and Prevention, Pre-exposure prophylaxis for the prevention of HIV in the United States—2014 clinical practice guideline. 2014.

2. Baeten JM et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. The Partners-PrEP study was one of the first large studies of heterosexual discordant couples indicating significant risk reduction with daily oral TDF or TDF/FTC PrEP. Substudies and open-label continuation phase from this study continue to contribute information regarding durability of effect and factors related to adherence.

3. Choopanya K et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90. This is the largest controlled trial demonstrating the efficacy and feasibility of oral PrEP for IDU in Thailand.

4. Grant RM et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. The iPrEX study was the first large placebo controlled trial to demonstrate risk reductions with PrEP and was conducted in MSM and TGW. Substudies have contributed substantially to information regarding correlates between adherence and protection in this population.

5. Thigpen MC et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34. The CDC TDF-2 study contributed to available data regarding efficacy of PrEP for prevention of heterosexual HIV transmission.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leveraging A Digital Pill System to Understand Prevention-Effective Adherence to Oral Hiv Pre-Exposure Prophylaxis Among Men Who Have Sex with Men with Substance Use;AIDS and Behavior;2024-07-10

2. Pre-Exposure Prophylaxis and HIV Prevention Among Key Populations in Nigeria;International Journal of Maternal and Child Health and AIDS;2024-06-28

3. Theory-driven formative research to support development of a pre-exposure prophylaxis (PrEP) demand creation campaign among young women in a South-African township;Gates Open Research;2022-07-27

4. Real-World User Experiences with a Digital Pill System to Measure PrEP Adherence: Perspectives from MSM with Substance Use;AIDS and Behavior;2022-01-28

5. A case report of a brain herniation secondary to cryptococcal meningitis with elevated intracranial pressure in a patient with Human Immunodeficiency Virus/Acquired immunodeficiency syndrome (HIV/AIDS);IDCases;2022